The latest numbers from the Democratic Republic of Congo (DRC) show the Ebola outbreak now stands at 9,066 cases 4,381 deaths. This is the second largest Ebola outbreak in history, following the 2014-2016 West Africa outbreak, which killed more than 11,000 people across Guinea, Liberia, and Sierra Leone.
The West Africa outbreak was caused by the more common Zaire strain of the virus. The current outbreak is caused by the Bundibugyo strain, which has no approved treatments or vaccines. The outbreak’s current case-fatality rate is 48.2%.
Phase 2/3 trial starts for Bundibugyo vaccine
Today CEPI, the Coalition for Epidemic Preparedness Innovations, announced preparations are under way for a phase 2/3 trial called Tumaini, which will evaluate the safety, immunogenicity and efficacy of vaccine candidates against Bundibugyo virus (BDBV), including Ervebo, the Zaire-targeting vaccine.
“Tumaini is designed as an adaptive platform trial, subject to ethical and regulatory approval,” CEPI said. “This allows several vaccine candidates to be evaluated in parallel within a single trial framework, which saves valuable time during an outbreak.” In addition to Ervebo, the trial will include at least two Bundibugyo-specific vaccine candidates.
Currently the Bravo study, a research project coordinated by Doctors Without Borders (Medecins sans Frontieres) is evaluating the effectiveness of the Ervebo vaccine against the Bundibugyo strain in North Kivu and Ituri province. Teams have vaccinated 857 frontline workers.